EUVIMEDEUVIMED entdecken
Crossref

Real-World Outcomes of Radiation After Chemoimmunotherapy for Stage III Lung Cancer

Giorgio Caturegli, Maureen Canavan, Oluwaseun F Ayoade, Daniel J Boffa, Benjamin J Resio

Clinical Lung Cancer · 2026-06 · 27 (5) · 48-54.e2

DOI: 10.1016/j.cllc.2026.03.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2026-06. Verfasst von Giorgio Caturegli und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT. Hauptthemen laut MEDLINE: Lung Neoplasms, Immunotherapy, Carcinoma, Non-Small-Cell Lung, Chemoradiotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Radiation following chemoimmunotherapy is not currently a standard treatment approach for Stage III non-small cell lung cancer (NSCLC). However, a need for this treatment scenario may arise in patients who underwent intended neoadjuvant chemoimmunotherapy but ultimately no resection. Here we evaluate the practice patterns and outcomes of radiation after chemoimmunotherapy as a nonsurgical option for stage III NSCLC patients. METHODS Clinical Stage III NSCLC patients diagnosed between 2018 and 2022 who received chemoimmunotherapy followed by thoracic radiation (or chemoradiation) were identified in the National Cancer Database. Characteristics were compared by Chi-squared test to patients receiving chemoimmunotherapy alone, chemoradiation followed by immunotherapy, or chemoimmunotherapy followed by surgery. Three-year overall survival was described with Kaplan-Meier curves. RESULTS In total, 1293 stage III patients received chemoimmunotherapy followed by radiation, while 5382 received chemoradiotherapy followed by immunotherapy, 1921 received chemoimmunotherapy, and 745 received chemoimmunotherapy followed by surgery. Most (1145, 88.6%) chemoimmunotherapy followed by radiation patients received a total radiation dose of ≥ 54 Gy, and 90-day mortality after radiation was 5.3%. Chemoimmunotherapy followed by radiation patients were more often staged T4 (41.5% vs. 34.8%, P < .001) or N3 (26.2% vs. 20.5%, P < .001) compared to chemoradiation/immunotherapy. Three-year overall survival was 51.7%. For reference, 3-year overall survival was 37.3% for chemoimmunotherapy alone, 56.0% for chemoradiation/immunotherapy, and 81.5% for chemoimmunotherapy/surgery. CONCLUSIONS Radiation after chemoimmunotherapy appears to be a substantially utilized, safe, and potentially effective regimen for Stage III NSCLC. Further study is indicated to evaluate chemoimmunotherapy followed by radiation as an alternative nonsurgical option for clinical stage III patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsImmunotherapyCarcinoma, Non-Small-Cell LungChemoradiotherapyHumansFemaleMaleNeoplasm StagingAgedMiddle AgedCombined Modality TherapySurvival RateRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

ChemotherapyImmunotherapyNon–small cell lung cancerSurgery

Autor:innen und Institutionen

  • Division of Thoracic Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT.
  • Division of Thoracic Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT. Electronic address: Benjamin.resio@yale.edu.

Zitieren

APA

Caturegli, G., Canavan, M., Ayoade, O. F., Boffa, D. J., & Resio, B. J. (2026). Real-World Outcomes of Radiation After Chemoimmunotherapy for Stage III Lung Cancer. Clinical Lung Cancer, 27(5), 48-54.e2. https://doi.org/10.1016/j.cllc.2026.03.016

Vancouver

Caturegli G, Canavan M, Ayoade OF, Boffa DJ, Resio BJ. Real-World Outcomes of Radiation After Chemoimmunotherapy for Stage III Lung Cancer. Clinical Lung Cancer. 2026;27(5):48-54.e2. doi:10.1016/j.cllc.2026.03.016

BibTeX
@article{Caturegli2026,
  author = {Caturegli, Giorgio and Canavan, Maureen and Ayoade, Oluwaseun F and Boffa, Daniel J and Resio, Benjamin J},
  title = {Real-World Outcomes of Radiation After Chemoimmunotherapy for Stage III Lung Cancer},
  journal = {Clinical Lung Cancer},
  year = {2026},
  volume = {27},
  number = {5},
  pages = {48--54.e2},
  doi = {10.1016/j.cllc.2026.03.016}
}
Kostenlos starten →